These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 28748122)

  • 21. Effect of Urate-Lowering Therapy on the Progression of Kidney Function in Patients With Asymptomatic Hyperuricemia: A Systematic Review and Meta-Analysis.
    Zhang L; An K; Mou X; Zhang M; Su Q; Li S
    Front Pharmacol; 2021; 12():795082. PubMed ID: 35115941
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy of Urate-Lowering Therapy in Patients With Chronic Kidney Disease: A Network Meta-Analysis of Randomized Controlled Trials.
    Yu X; Gu M; Zhu Y; Zhang L; Kong W; Zou Y
    Clin Ther; 2022 May; 44(5):723-735.e6. PubMed ID: 35610080
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association.
    Mallat SG; Al Kattar S; Tanios BY; Jurjus A
    Curr Hypertens Rep; 2016 Oct; 18(10):74. PubMed ID: 27696189
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of Hyperuricemia in Chronic Kidney Disease.
    Ramirez-Sandoval JC; Madero M
    Contrib Nephrol; 2018; 192():135-146. PubMed ID: 29393124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacotherapy for hyperuricemia in hypertensive patients.
    Gois PH; Souza ER
    Cochrane Database Syst Rev; 2013 Jan; (1):CD008652. PubMed ID: 23440832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [URATE AS A POTENTIAL RISK FACTOR OF CARDIOVASCULAR AND RENAL DISEASES].
    Butković M
    Acta Med Croatica; 2016 Dec; 70(4-5):233-9. PubMed ID: 29087102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative effect of allopurinol and febuxostat on long-term renal outcomes in patients with hyperuricemia and chronic kidney disease: a systematic review.
    Hu AM; Brown JN
    Clin Rheumatol; 2020 Nov; 39(11):3287-3294. PubMed ID: 32418037
    [TBL] [Abstract][Full Text] [Related]  

  • 28. To Treat or Not to Treat? Effect of Urate-Lowering Therapy on Renal Function, Blood Pressure and Safety in Patients with Asymptomatic Hyperuricemia: A Systematic Review and Network Meta-Analysis.
    Tien YY; Shih MC; Tien CP; Huang HK; Tu YK
    J Am Board Fam Med; 2022; 35(1):140-151. PubMed ID: 35039419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease　- Japanese Guideline on the Management of Asymptomatic Hyperuricemia.
    Hisatome I; Li P; Miake J; Taufiq F; Mahati E; Maharani N; Utami SB; Kuwabara M; Bahrudin U; Ninomiya H
    Circ J; 2021 Jan; 85(2):130-138. PubMed ID: 33342914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Associations Between Hyperuricemia and Chronic Kidney Disease: A Review.
    Prasad Sah OS; Qing YX
    Nephrourol Mon; 2015 May; 7(3):e27233. PubMed ID: 26290849
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of asymptomatic hyperuricemia complicated by renal damage: a controversial issue.
    Hu C; Wu X
    Int Urol Nephrol; 2019 Dec; 51(12):2227-2233. PubMed ID: 31463702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of hyperuricemia on chronic kidney disease and atherosclerotic cardiovascular disease.
    Nishizawa H; Maeda N; Shimomura I
    Hypertens Res; 2022 Apr; 45(4):635-640. PubMed ID: 35046512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis.
    Liu X; Zhai T; Ma R; Luo C; Wang H; Liu L
    Ren Fail; 2018 Nov; 40(1):289-297. PubMed ID: 29619870
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Uric acid and chronic kidney disease: which is chasing which?
    Johnson RJ; Nakagawa T; Jalal D; Sánchez-Lozada LG; Kang DH; Ritz E
    Nephrol Dial Transplant; 2013 Sep; 28(9):2221-8. PubMed ID: 23543594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mini Review: Reappraisal of Uric Acid in Chronic Kidney Disease.
    Goldberg A; Garcia-Arroyo F; Sasai F; Rodriguez-Iturbe B; Sanchez-Lozada LG; Lanaspa MA; Johnson RJ
    Am J Nephrol; 2021; 52(10-11):837-844. PubMed ID: 34673651
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does uric acid-lowering treatment slow the progression of chronic kidney disease? A meta-analysis of randomized controlled trials.
    Bignardi PR; Ido DH; Garcia FAL; Braga LM; Delfino VDA
    Nefrologia (Engl Ed); 2023; 43(2):167-181. PubMed ID: 36564223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urate Transporter ABCG2 Function and Asymptomatic Hyperuricemia: A Retrospective Cohort Study of CKD Progression.
    Ohashi Y; Kuriyama S; Nakano T; Sekine M; Toyoda Y; Nakayama A; Takada T; Kawamura Y; Nakamura T; Matsuo H; Yokoo T; Ichida K
    Am J Kidney Dis; 2023 Feb; 81(2):134-144.e1. PubMed ID: 35810827
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Uric Acid Lowering on Renin-Angiotensin-System Activation and Ambulatory BP: A Randomized Controlled Trial.
    McMullan CJ; Borgi L; Fisher N; Curhan G; Forman J
    Clin J Am Soc Nephrol; 2017 May; 12(5):807-816. PubMed ID: 28320765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uric acid and progression of chronic kidney disease.
    Weaver DJ
    Pediatr Nephrol; 2019 May; 34(5):801-809. PubMed ID: 29931555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vascular Function and Uric Acid-Lowering in Stage 3 CKD.
    Jalal DI; Decker E; Perrenoud L; Nowak KL; Bispham N; Mehta T; Smits G; You Z; Seals D; Chonchol M; Johnson RJ
    J Am Soc Nephrol; 2017 Mar; 28(3):943-952. PubMed ID: 27620990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.